Acurastem wins $7.5M to advance ALS treatment to clinical trials
WHY IT MATTERS
This funding accelerates a potential new ALS treatment toward human trials, offering hope for patients with TDP-43-related ALS who currently have limited therapeutic options beyond supportive care.
A company called Acurastem received $7.5 million in funding to help develop a new treatment called AS-241 for ALS (a disease that affects nerve cells that control muscles). Early lab studies show this treatment might be able to fix problems caused by a faulty protein called TDP-43. The company is now working to get this treatment ready to test in patients.
Acurastem has received $7.5 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance AS-241, its lead clinical candidate for amyotrophic lateral sclerosis (ALS) and related diseases, toward clinical trials. The grant was supported by cell-based studies showing that AS-241 can restore certain ALS-related defects caused by problems with the TDP-43 protein, […] The post Acurastem wins $7.5M to advance ALS treatment to clinical trials appeared first on ALS N